HUTCHMED (China) (HMDCF) Change in Account Payables (2020 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Change in Account Payables came in at -$3.0 million in Q1 2021, down 156.77% year-over-year from $5.2 million in Q1 2020, and down 156.77% quarter-over-quarter from -$1.2 million in Q1 2020.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Change in Account Payables (2020 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Change in Account Payables for 2 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 7.11 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |